138 related articles for article (PubMed ID: 37013346)
1. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
[TBL] [Abstract][Full Text] [Related]
2. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
3. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
6. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
[TBL] [Abstract][Full Text] [Related]
7. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
8. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
11. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.
Vera O; Rodriguez-Antolin C; de Castro J; Karreth FA; Sellers TA; Ibanez de Caceres I
Epigenetics; 2018; 13(3):251-263. PubMed ID: 29436261
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
13. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.
Dai W; Teodoridis JM; Graham J; Zeller C; Huang TH; Yan P; Vass JK; Brown R; Paul J
BMC Bioinformatics; 2008 Aug; 9():337. PubMed ID: 18691414
[TBL] [Abstract][Full Text] [Related]
14. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
15. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
[TBL] [Abstract][Full Text] [Related]
17. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas.
Chen HY; Shao CJ; Chen FR; Kwan AL; Chen ZP
Int J Cancer; 2010 Apr; 126(8):1944-1954. PubMed ID: 19626585
[TBL] [Abstract][Full Text] [Related]
18. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
19. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
20. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
